Objective: This study was aimed at characterizing alterations in the immunohistochemical expression of p16 in carcinoma ex-pleomorphic adenomas.
Study Design: A selected series of 27 cases of carcinoma ex-pleomorphic adenomas were examined.
Results: The results showed that p16 expression in non tumour duct cells was strongly positive nuclear staining in 23 (85%) cases out of 27 cases, that 3 (11.1%) had moderate staining, and that 1 (3.7%) had weak staining. p16 expression in carcinoma ex-pleomorphic adenomas was indicated as a negative nuclear staining in 22 (81.4%) cases out of 27cases, and 5 (18.5%) cases expressed moderate staining.
Conclusion: This study suggests that alteration of p16 expression is detected in carcinoma ex-pleomorphic adenomas. p16 has a role in development of carcinoma ex-pleomorphic adenomas.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919315 | PMC |
| http://dx.doi.org/10.7860/JCDR/2013/7380.3851 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: There is no current standard treatment regimen for carcinoma ex pleomorphic adenoma (CXPA) of the lacrimal gland. Neoadjuvant intraarterial cytoreductive chemotherapy (IACC) followed by multimodal therapy has achieved good locoregional control in adenoid cystic carcinoma of the lacrimal gland. We reviewed our experience with neoadjuvant IACC followed by multimodal therapy for CXPA of the lacrimal gland.
View Article and Find Full Text PDFExpression of toll-like receptors in recurrent pleomorphic adenoma and carcinoma ex pleomorphic adenoma.
APMIS
January 2025
Department of Pathology, University Hospital of Helsinki and Turku, Helsinki, Finland.
Pleomorphic adenoma (PA) is a benign salivary gland tumour that may recur or undergo malignant transformation (CXPA). Toll-like receptors (TLR) mediate immune responses triggered by various agents such as viruses and are related to tumour formation either by stimulating or suppressing their growth, with variation across different tumour entities. We compared TLR immunohistochemical expression in PA, its recurrent counterparts and CXPA and evaluated the effect of virus presence in these tumours.
View Article and Find Full Text PDFUnderstanding and overcoming the pitfalls in the diagnosis of pleomorphic and carcinoma ex-pleomorphic adenoma of salivary glands.
Histopathology
December 2024
Department of Pathology, Institut of Pathologie Multisite, Hospices Civils de Lyon, University South Lyon Hospital, Pierre-Bénite, France.
The study illustrates a recurrent pitfall in the diagnosis of pleomorphic adenoma and carcinoma ex pleomorphic adenoma.
View Article and Find Full Text PDFTRPS1 Immunohistochemistry in Salivary Gland Neoplasms: Analysis on Cytology Cell Blocks and Surgical Follow-Up Correlation.
Diagn Cytopathol
December 2024
Department of Pathology and Laboratory Medicine, Northwell Health, Donald and Barbara Zucker School of Medicine at Hofstra, Greenvale, New York, USA.
Introduction: In this study we aim to analyze the TRPS1 immunostaining of salivary gland tumors (SGT) on cytology cell blocks and compare the staining pattern on subsequent surgical resections.
Methods: Malignant SGTs, oncocytomas and basal cell adenomas diagnosed on fine needle aspiration were retrieved from 2019 to 2021 database. Cases with surgical follow-up were selected.
Gargantuan carcinoma ex-pleomorphic adenoma of the submandibular gland: Case report and review of literature.
Am J Otolaryngol
December 2024
Department of Surgery, Division of Otolaryngology, Dayton, OH, USA. Electronic address:
Introduction: Pleomorphic adenoma is the most common neoplasm of the major salivary glands, and can undergo malignant transformation to carcinoma ex-pleomorphic adenoma (CXPA) in untreated patients.
Case Presentation: Our case describes a 56-year-old male with a 15-year history of slowly growing expansive right-sided neck. He underwent excision of the neck mass, neck dissection, and pectoralis flap reconstruction.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!